JACC Heart FailureYehya et al.Original Research

Christopher M. O’Connor works in Heart Failure / Cardiomyopathy affiliated with Duke Medical Center.
Christopher M. O'Connor, MD, is President of Inova Schar Heart and Vascular at Inova Health System and Adjunct Professor of Medicine at Duke University School of Medicine. He joined Inova in April 2015 after 31 years at Duke University Medical Center. He completed his MD at the University of Maryland School of Medicine and residency and cardiology fellowship at Duke University.
972 pubs · 65,745 cites · h-index 129
MD
University of Maryland School of Medicine
1983
BS
University of Maryland, College Park
1979
President, Inova Schar Heart and Vascular
Inova Health System · 2015 - Present
Adjunct Professor of Medicine
Duke University School of Medicine · 2015 - Present
Director, Duke Heart Center
Duke University Medical Center · 2007 - 2015
Chief, Division of Cardiology
Duke University Medical Center · 2010 - 2015
Chief, Division of Clinical Pharmacology
Duke University Medical Center · 2001 - 2015
JACC Heart FailureYehya et al.Original Research
Circulation Heart FailureAbdelnoor et al.Original Research
Blood Pressure and Hypertension Studies · Sprint (United States)
If you decrease the BP too low, then the flow of blood in the coronary arteries and the oxygen supply to the myocardium will decline. In patients with CAD and the elderly, diastole is the time when the myocardium fills with blood. Caution should be observed in lowering the diastolic BP in patients with CAD or in elderly patients who presumably have more atheroma than younger patients, and the physician should be alert to signs of ischemia as the BP goes down. The diastolic BP should not really be lowered below about 60 mm Hg.
Journal of the American College of CardiologyRosendorff et al.
Heart Failure / Cardiomyopathy · Université Claude Bernard Lyon 1
The authors demonstrate that nesiritide had no net effect on diuresis in a study group of very sick heart failure patients (median NT-proBNP approximately 4,500 pg/ml) with concomitant, moderately impaired renal function. They further conclude that the dose of loop diuretics, degree of congestion, blood pressure, and crude degree of neurohumoral stimulation assessed by blood urea nitrogen (BUN) all influence the amount of diuresis.
Journal of the American College of CardiologyGottlieb et al.
European Journal of Heart FailureSenni et al.Original Research
European Journal of Heart FailureEzekowitz et al.RCT
Does vericiguat reduce the composite of cardiovascular death or first HF hospitalization in ambulatory patients with HFrEF, and is the effect modified by background GDMT class, dose attainment, or intensity?
This exploratory analysis of VICTOR compared vericiguat with placebo across standard medication levels in 6,105 outpatients with reduced ejection fraction heart failure without recent worsening. Baseline therapy was high, including 94% on beta blockers and 59% on SGLT2 inhibitors. Overall, the neutral effect of vericiguat on heart death or first hospital stay for heart failure did not change by drug class, target dose or intensity. Subgroup power was limited, so these findings should not guide medication sequencing.
JACCO’Connor et al.cohort
Can a simplified clinical risk score calculated at hospital discharge accurately predict 6-month mortality in patients with advanced heart failure?
May aid discharge risk stratification in advanced HF; extends prior models but leaves open effects on outcomes.
JACCStevenson et al.cohort
How do patient preferences for survival versus quality of life change after hospitalization for advanced heart failure?
Preferences may shift toward survival after HF discharge; leaves open whether PAC-guided therapy influences time trade-offs.
JACCWhellan et al.cohort
Does a combined heart failure device diagnostic algorithm predict subsequent heart failure hospitalizations in patients with systolic left ventricular dysfunction receiving CRT-defibrillators?
Device alerts flagged high near-term HF hospitalization risk in CRT-D patients; leaves open whether acting on alerts reduces events.
Mechanical Circulatory Support Devices · Kaiser Permanente San Francisco Medical Center
These findings refine the ability to apply CPX results when making clinical decisions, and tailor interpretations of the results to a particular patient. One of the most important findings from this study is the sex-related differences. Exercise capacity appears to be a particularly important predictor in women. Peak VO2 is a strong predictor as well; however, the cutpoint used to identify women at increased risk of mortality appears to be much lower than current values.
Journal of the American College of CardiologyKeteyian et al.
JACCGattis et al.Cohort Study
Does predischarge initiation of carvedilol improve beta-blocker use at 60 days in patients hospitalized for heart failure?
Clinical evaluation reveals benefits of starting carvedilol before discharge in decompensated heart failure, highlighting improved post-discharge treatment adherence.
Heart Failure / Cardiomyopathy · Merck & Co., Inc., Rahway, NJ, USA (United States)
By studying patients without recent heart failure hospitalizations, the phase 3 VICTOR trial expands our understanding of Verquvo across the full spectrum of chronic heart failure patients with reduced ejection fraction. Together with the previously communicated results in VICTORIA in patients with worsening chronic heart failure and ejection fraction less than 45% following a worsening heart failure event, the results today provide valuable information and add to our understanding of heart failure and Verquvo.
The LancetButler et al.
JACCGreene et al.cohort
Does longer duration of heart failure diagnosis worsen early dyspnea relief and 180-day mortality in patients hospitalized for acute heart failure compared to recently diagnosed heart failure?
Recent HF diagnosis was associated with better dyspnea relief and survival; leaves open whether chronicity should stratify acute HF trials or risk models.
Cardiac Health and Mental Health · National Natural Science Foundation of China
These studies demonstrate how important it is for clinicians to understand the connection between significant emotional stress and pathophysiologic processes. We can't just say, 'Oh, this patient's chest pain or shortness of breath are just a somatic symptom of mental problems'; there is a pathologic process underlying these symptoms, and if it's not taken care of appropriately, these patients are more likely to die of heart attack, stroke, or heart failure.
Journal of the American College of CardiologyJiang et al.
Journal of the American Heart AssociationNguyen et al.RCT
Does a 200J rectilinear biphasic waveform shock improve first shock cardioversion success compared to a 360J biphasic truncated exponential shock in adults with symptomatic atrial fibrillation?
Comparable first-shock success with 200J RBW versus 360J BTE supports either waveform for AF cardioversion; extends RCT data on energy delivery.
JACCAhmad et al.cohort
Does a structured exercise program improve clinical outcomes differentially across distinct clinical phenotypes of chronic systolic heart failure?
Cluster analysis of chronic heart failure patients identifies distinct clinical phenotypes with varying risk profiles and differential responses to exercise therapy, highlighting the need for improved disease phenotyping.
JACCKeteyian et al.cohort
Does a greater volume of exercise reduce mortality or hospitalization in patients with chronic systolic heart failure?
May support moderate exercise targets in systolic HF; leaves open causality and optimal dosing for randomized trials.
JACCHernandez et al.cohort
Does newly initiated beta-blocker therapy at hospital discharge reduce 1-year mortality and all-cause rehospitalization in elderly patients hospitalized for heart failure with left ventricular systolic dysfunction or preserved systolic function?
Beta-blocker initiation at discharge was associated with lower mortality in elderly HF with LVSD but not preserved function; leaves open randomized confirmation before practice change.
EHJSamad et al.cohort
Does mitral valve surgery improve long-term event-free survival in patients with moderate or severe functional mitral regurgitation and severe left ventricular dysfunction?
In patients with moderate or severe functional mitral regurgitation and severe LV dysfunction, mitral valve surgery is associated with improved long-term event-free survival compared to medical therapy.
Mechanical Circulatory Support Devices · United Lincolnshire Hospitals NHS Trust
If you can, you always want to continue the beta blocker or the ACE inhibitor, because studies have shown us that the likelihood for patients to be on these medications 90 days later is dismal. But you also need to look at the patient. If the patient is in cardiogenic shock, their beta blocker should be stopped.
Journal of the American College of CardiologyFonarow et al.